Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience

Next Previous
Search
Trial Profile

Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vadadustat (Primary) ; Darbepoetin alfa; Epoetin alfa; Methoxy polyethylene glycol-epoetin beta
  • Indications Anaemia
  • Focus Adverse reactions
  • Acronyms VOICE

    • Most Recent Events

    • 03 Dec 2024 According to an Akebia Therapeutics media release, in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. The company expects to begin treating CKD anemia patients on dialysis with Vafseo ahead of its anticipated market launch in January 2025.
    • 03 Dec 2024 Status changed from not yet recruiting to recruiting, according to an Akebia Therapeutics media release.
    • 05 Sep 2024 According to an Akebia Therapeutics media release, the company announced plans to begin a collaborative clinical trial of recently approved Vafseo. The first patient in this trial is expected to be enrolled this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top